CNBCA

Cat. No.: HY-155098

Molecular Formula: $C_{26}H_{34}O_5$

Molecular Weight: 426.55

Target: SHP2

Pathway: Protein Tyrosine Kinase/RTK

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	CNBCA is a potent, selective, competitive SHP2 enzyme inhibitor, with the IC_{50} of 0.87 μM. CNBCA binds to full-length SHP2 and inhibits enzyme activity. CNBCA inhibits pAkt and pERK1/2, and the cell growth of BT474 and MDA-MB468 cells. CNBCA can be used for breast cancer study[1].
IC_{50} & Target	0.87 μM (SHP2)[1]
In Vitro	CNBCA (0.25, 0.50, 1, 2 μM, 48 h) inhibits SHP2 mediated Akt and ERK1/2 activation in the BT474 and MDA-MB468 cells with an approximate IC_{50} of 1.0 μM[1]. CNBCA (500 nM, 24-72 h) inhibits cell growth in the BT474 and MDA-MB468 cells[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line:	BT474 and MDA-MB468 cells
Concentration:	0.25, 0.50, 1, 2 μM
Incubation Time:	48 h
Result:	Inhibited SHP2 mediated Akt and ERK1/2 activation.

REFERENCES

[1]. Dhanaji M, et al. Targeting SHP2 with an Active Site Inhibitor Blocks Signaling and Breast Cancer Cell Phenotypes. ACS Bio Med Chem Au 2023

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA